Topical Prostaglandin Analogues and Conjunctival Inflammation in Uveitic Glaucoma

Simon RJ Taylor*, 1 , 2 , 3 , Avinash Gurbaxani3, Ahmed Sallam3, Sue Lightman2 , 3 , 4
1 Division of Immunology & Inflammation, Faculty of Medicine, Imperial College London, London, UK
2 Royal Surrey County Hospital NHS Foundation Trust, Guildford, Surrey, UK
3 Moorfields Eye Hospital, City Road, EC1V 2PD, London, UK
4 UCL Institute of Ophthalmology, 11-43 Bath Street, EC1V 9EL, London, UK

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 3226
Abstract HTML Views: 2629
PDF Downloads: 741
Total Views/Downloads: 6596
Unique Statistics:

Full-Text HTML Views: 1721
Abstract HTML Views: 1470
PDF Downloads: 510
Total Views/Downloads: 3701

Creative Commons License
© Taylor et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Imperial College London Faculty of Medicine, Room 5N8B, 5th Floor Commonwealth Building, Hammersmith Hospital, London W12 0NN, UK; Tel: +44 (0) 20 8383 2306; Fax: +44 (0) 20 7566 2266; E-mail:



A pilot study to determine whether topical prostaglandin analogues alter the expression of conjunctival inflammatory markers in patients with uveitic glaucoma.


Prospective, single-masked case series of 20 patients with uveitis and secondary raised intraocular pressure. Participants were divided into four groups of five patients dependent on their use of topical medication: (1) prostaglandin analogues only, (2) corticosteroids only, (3) both prostaglandin analogues and corticosteroids, (4) no topical medication. Conjunctival cells were harvested by impression cytology and were examined for inflammatory markers (CD3, CD54, HLA-DR, CCR4, CCR5) by flow cytometry. A tear fluid sample was also examined for inflammatory cytokines (IL-12p70, IL-2, IL-10, IL-8, IL-6, IL-4, IL-5, IFN-gamma, IL-1beta, IFN-alpha, IFN-beta) by multiplex bead arrays.


All groups demonstrated increased markers of conjunctival inflammation. There was no significant difference in levels of any inflammatory markers between the four groups, suggesting that the use of topical prostaglandin analogues does not increase conjunctival levels of inflammation beyond those already seen in uveitis.


The use of topical prostaglandins does not appear to induce conjunctival inflammation over that which is already present in patients with uveitic glaucoma. This supports the use of topical prostaglandin analogues in patients with uveitic glaucoma, indicating that their use is unlikely to adversely affect subsequent glaucoma filtration surgery through the induction of chronic conjunctival inflammation.

Keywords:: Uveitic glaucoma, prostaglandin analogues, conjunctival inflammation, trabeculectomy.